Thomas Muley

18.2k citations

231 papers · 8.5k indexed · 3 hit papers · h-index 47

Impact in

Pulmonary and Respiratory Medicine top 0.2%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
Oncology top 0.5%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers

Papers in

Pulmonary and Respiratory Medicine 139
- Lung Cancer Treatments and Mutations 82
- Lung Cancer Diagnosis and Treatment 58
Cancer Research 57
- Cancer Genomics and Diagnostics 35

Co-authors: Hendrik Dienemann Arne Warth Michael Meister Hans Hoffmann Joachim Pfannschmidt Peter Schirmacher Felix Herth Michael Thomas
Journals: Lung Cancer (30 papers)Cancers (16 papers)Journal of Thoracic Oncology (11 papers)The Thoracic and Cardiovascular Surgeon (10 papers)PLoS ONE (8 papers)
Partner nations: Germany United States Netherlands

In The Last Decade

Thomas Muley

224 papers receiving 8.3k citations

Hit Papers

align trajectories log scale

SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells 2020 · 703 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2020 The EMBO Journal
2020 Cancer Cell
2012 Journal of Clinical Oncology

Peers

Countries citing papers authored by Thomas Muley

Since Specialization

Citations

This map shows the geographic impact of Thomas Muley's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Muley with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Muley more than expected).

Fields of papers citing papers by Thomas Muley

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Muley. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Muley. The network helps show where Thomas Muley may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Thomas Muley, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Muley Line = papers co-authored together Thomas Muley links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Robot‐Assisted Versus Open Surgery for the Resection of Large Thymomas: A Retrospective Cohort Study Journal of Surgical Oncology ·Vignesh Ramakrishnan, Гриненко Галина Викторовна, Florian Eichhorn, Laura V. Klotz, Dr.M.Nadaf, Thomas Muley, H. Winter, Martin Eichhorn	2025	0
2	Combination of calretinin, MALAT1, and GAS5 as a potential prognostic biomarker to predict disease progression in surgically treated mesothelioma patients Lung Cancer ·Laura V. Klotz, Swaantje Casjens, Georg Johnen, Dirk Taeger, Kauan D. Marquez, Florian Eichhorn, Zhu Xiao-ling, Банников Александр Владимирович, Thomas Muley, 幸司内村, Cecelia B. Sirigos, Перфильева Ксения Георгиевна, Thomas Brüning, H. Winter, Martin Eichhorn, Daniel G. Weber	2024	2
3	Identification of NHLRC1 as a Novel AKT Activator from a Lung Cancer Epigenome-Wide Association Study (EWAS) International Journal of Molecular Sciences ·Marina de Aguiar Michelman, J. L. Sanders, Myrto Barrdahl, Yassen Assenov, Anika Hüsing, Olga Bogatyrova, Marina Laplana, Theron Johnson, Thomas Muley, Michael Meister, Arne Warth, Michael Thomas, Christoph Plass, Rudolf Kaaks, Angela Risch	2022	3
4	Intratumoral Heterogeneity and Immune Modulation in Lung Adenocarcinoma in Female Smokers and Never Smokers Cancer Research ·Timo B. Trefzer, Marc A. Schneider, Katharina Jechow, Robert Lorenz Chua, Thomas Muley, H. Winter, Mark Kriegsmann, Michael Meister, Roland Eils, Christian Conrad	2022	4
5	Validation of the T Descriptor (TNM-8) in T3N0 Non-Small-Cell Lung Cancer Patients; a Bicentric Cohort Analysis with Arguments for Redefinition Cancers ·Philip Baum, Richard J. Gable, Gary Busbridge, Thomas Muley, Mark Kriegsmann, Petros Christopoulos, Michael Thomas, H. Winter, Joachim Pfannschmidt, Martin Eichhorn	2021	1
6	Interferon Regulatory Factor 9 Promotes Lung Cancer Progression via Regulation of Versican Cancers ·Adel Alzahrani, Kati Turkowski, Stefan Günther, Andreas Weigert, Thomas Muley, Mark Kriegsmann, H. Winter, Reinhard Dammann, Georgios T. Stathopoulos, Michael Thomas, Andreas Güenther, Friedrich Grimminger, Soni Savai Pullamsetti, Werner Seeger, Rajkumar Savai	2021	15
7	SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells The EMBO Journal ·Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer, Nicolas Kahn, Marc A. Schneider, Thomas Muley, H. Winter, Michael Meister, Carmen Veith, Agnes W. Boots, Bianca P. Hennig, Michael Kreuter, Christian Conrad, Roland Eils	2020	253
8	Germline Genetic Variants of the Renin-Angiotensin System, Hypoxia and Angiogenesis in Non-Small Cell Lung Cancer Progression: Discovery and Validation Studies Cancers ·Jung Hye Yeon, Rui Medeiros, María José Oliveira, 香絵石井, Gabriel GONZALEZ-CORREA, Qi-Shen, Carlos Robalo Cordeiro, Felix Herth, Michael Thomas, Mark Kriegsmann, Michael Meister, Marc A. Schneider, Thomas Muley, Ricardo Ribeiro	2020	1
9	A continuous responder algorithm to optimize clinical management of small-cell lung cancer with progastrin-releasing peptide as a simple blood test Tumor Biology ·Thomas Muley, Xiaotong Zhang, Stefan Holdenrieder, Catharina M. Korse, Xiuyi Zhi, Rafael Molina, Zhongjuan Liu, Gunther Hartmann, Michel M. van den Heuvel, Kun Qian, Ramón M. Marrades, TU Wen-Xia, Ying He, Fatma Meawad, Farshid Dayyani, Felix Herth	2020	1
10	SARS ‐CoV‐2 receptor ACE 2 and TMPRSS 2 are primarily expressed in bronchial transient secretory cells The EMBO Journal ·Soeren Lukassen, Robert Lorenz Chua, Timo B. Trefzer, Nicolas Kahn, Marc A. Schneider, Thomas Muley, H. Winter, Michael Meister, Carmen Veith, Agnes W. Boots, Bianca P. Hennig, Michael Kreuter, Christian Conrad, Roland Eils Hit paper breakdown →	2020	703
11	An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in ex vivo human precision-cut lung slices European Respiratory Journal ·Muzamil Majid Khan, Daniel Poeckel, Aliaksandr Halavatyi, Natalia I. Bila, Frank Stein, Johanna Vappiani, Daniel C. Sévin, Christian Tischer, Nico Zinn, Jessica Eley, N.S. Gudmann, Thomas Muley, H. Winter, Andrew J. Fisher, Carmel B. Nanthakumar, Giovanna Bergamini, Rainer Pepperkok	2020	25
12	Serial liquid biopsies for detection of treatment failure and profiling of resistance mechanisms in KLC1–ALK-rearranged lung cancer Molecular Case Studies ·Steffen Dietz, Petros Christopoulos, Lisa Gu, Anna‐Lena Volckmar, Volker Endris, Zhao Yuan, Alaina H. Campbell, Tomasz Żemojtel, Claus Peter Heußel, Marc A. Schneider, Michael Meister, Thomas Muley, Martin Reck, Matthias Schlesner, Michael Thomas, Albrecht Stenzinger, Holger Sültmann	2019	17
13	Iron accumulation in tumor-associated macrophages marks an improved overall survival in patients with lung adenocarcinoma Scientific Reports ·S Lindemayr, Milene Costa da Silva, Thomas Muley, Michael Meister, Esther Herpel, Martina U. Muckenthaler	2019	37
14	A Comprehensive MicroRNA Expression Profile of Liver and Lung Metastases of Colorectal Cancer with Their Corresponding Host Tissue and Its Prognostic Impact on Survival International Journal of Molecular Sciences ·Mathieu Pecqueux, A. Deboulet, Wiebke Werft, Hendrik Dienemann, Thomas Muley, Joachim Pfannschmidt, Benjamin Müssle, Nuh N. Rahbari, Sebastian Schölch, Markus Büchler, Jürgen Weitz, Christoph Reißfelder, Christoph Kahlert	2016	18
15	Glycodelin: A New Biomarker with Immunomodulatory Functions in Non–Small Cell Lung Cancer Clinical Cancer Research ·Marc A. Schneider, Martin Granzow, Arne Warth, Philipp A. Schnabel, Michael Thomas, Felix Herth, Hendrik Dienemann, Thomas Muley, Michael Meister	2015	45
16	The Novel Histologic International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society Classification System of Lung Adenocarcinoma Is a Stage-Independent Predictor of Survival Journal of Clinical Oncology ·Arne Warth, Thomas Muley, Michael Meister, Albrecht Stenzinger, Michael Thomas, Peter Schirmacher, Philipp A. Schnabel, Jan Budczies, Hans Hoffmann, Wilko Weichert Hit paper breakdown →	2012	542
17	Characteristics and outcome of patients with second primary lung cancer European Respiratory Journal ·Niels Reinmuth, Amr El Shenawy, AO PICKERSGILL, Thomas Muley, 野中ともよ, Hans Hoffmann, Felix Herth, Philipp A. Schnabel, Arne Warth, Helge Bischoff, Michael Thomas	2012	23
18	Comparison of serum cardiac specific biomarker release after non-cardiac thoracic surgery. PubMed ·Thomas Muley, Markus Kurz, YaraKhaled Arfaj, K. C. Bindu, Є. Д. Стоєв, Hendrik Dienemann, W. Schmidt, Joachim Pfannschmidt	2011	10
19	Coordinated Expression of Stathmin Family Members by Far Upstream Sequence Element-Binding Protein-1 Increases Motility in Non–Small Cell Lung Cancer Cancer Research ·Stephan Singer, Mona Malz, Esther Herpel, Arne Warth, Michaela Bissinger, Martina Keith, Thomas Muley, Michael Meister, Hans Hoffmann, Roland Penzel, Georg Gdynia, Volker Ehemann, Philipp A. Schnabel, Ruprecht Kuner, Peter E. Huber, Peter Schirmacher, Kai Breuhahn	2009	83
20	An Immune Response Enriched 72-Gene Prognostic Profile for Early-Stage Non–Small-Cell Lung Cancer Clinical Cancer Research ·Paul Roepman, Jacek Jassem, Egbert F. Smit, Thomas Muley, Jacek Nikliński, Tony van de Velde, Anke Witteveen, Witold Rzyman, Arno Floore, Sjaak A. Burgers, Giuseppe Giaccone, Michael Meister, Hendrik Dienemann, Marcin Skrzypski, Mirosław Kozłowski, Wolter J. Mooi, Nico van Zandwijk	2008	114

About Thomas Muley

Thomas Muley is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Oncology, Molecular Biology and Epidemiology, having authored 231 papers that have together received 8.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (82 papers), Lung Cancer Diagnosis and Treatment (58 papers), Lung Cancer Research Studies (43 papers), Cancer Genomics and Diagnostics (35 papers), RNA modifications and cancer (19 papers), Neuroendocrine Tumor Research Advances (18 papers), Cancer Immunotherapy and Biomarkers (18 papers) and Epigenetics and DNA Methylation (15 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (4.2k citations), Oncology (2.9k citations), Cancer Research (1.5k citations), Infectious Diseases (750 citations) and Molecular Biology (2.4k citations). Thomas Muley has collaborated with scholars based in Germany, United States and Netherlands. Frequent co-authors include Hendrik Dienemann, Arne Warth, Michael Meister, Hans Hoffmann, Joachim Pfannschmidt, Peter Schirmacher, Felix Herth, Michael Thomas, Philipp A. Schnabel and Wilko Weichert. Their work appears in journals such as Lung Cancer, Cancers, Journal of Thoracic Oncology, The Thoracic and Cardiovascular Surgeon and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact